This will be a welcome addition to the literature. I apologize for reiterating an issue in the above paragraph but the largest head to head study of iron safety ever done was recently published in Am J Heme (ferumoxytol versus ferric carboxymaltose). If you are going to use trade names you need to add the generic as well as different trade names for the same formulation such as Ferinject in Europe is InjectoFer in US and INFeD (LMWID) is CosmoFer in Europe.
I predict you will show IV iron is not associated with increased infection unless over utilized as it has been in nephrology with a decrease in ESA utilization.
REVIEWER

Simon Roger Gosford Renal Research
REVIEW RETURNED
24-Jul-2018
GENERAL COMMENTS
there are some typographical errors. is the update using the exact same search criteria as the first meta-analysis? also, i couldn't see reference to iron polymaltose or Triferic (ferric pyrophosphate citrate), the later used in haemodialysis patients, although not intravenous, but entering the circulation via the dialysate. it will be a useful update.
REVIEWER
Guenter Weiss
Medical University of Innsbruck, Internal Medicine II REVIEW RETURNED 25-Oct-2018
GENERAL COMMENTS
This is an important study aiming to perform a systematic review of recent trials toward the risk of infection upon intravenous iron therapy. The protocol is clear and well structured. I would recommend to add a few aspects or to consider them for inclusion into the analysis. 1) Comparison of the risk of infection between trials treating true iron deficiency (= iron deficiency anemia without any signs of inflammation or concomitant disease except bleeding disorders or pregnancy) and studies using i.v. iron in functional iron deficiency (Chronic kidney disease, cancer, auto-immune diseases , even underlying infectious diseases?, congestive heart failure, intensive care patients with inflammation)
2) It would be also of interest to extract information from the trials on a dose effect of intravenous iron (cumulative dosage and risk of infection) and in regard to the mode of administration---low dose/continuous versus bolus application (which became a challenging issue in nephrology for the treatment of dialysis patients) 3) Further, an evaluation should be also made according to environmental factors, such as the endemic burden of infections REVIEWER Neri Alvarez-Villalobos Universidad Autónoma de Nuevo León, Monterrey, 64460, México.
REVIEW RETURNED
12-Dec-2018
GENERAL COMMENTS
Dr. Akshay Shah et al. report a prospective analysis of safety outcomes of intravenous iron preparations, a continuation from a previous systematic review, in which they aimed to assess the risk of infection among intravenous iron vs. non-iron/ placebo or oral iron.
The study question is interesting and concise; the manuscript is mostly well written and easy to understand, nevertheless, there are a few aspects that need to be clarified:
1. In the introduction, the discussion of several authors results deviates the background from the main purpose and justification of the research.
2.-Page 4 row 42 there is a misspelling word: atopic instead a topic.
3.-Page 4 row 42 they include (REF), and they should include the number of references, (that makes me feel that the protocol is not finished yet).
4.-Page 5 row 15 the reference six is misspelled (6).
included and the study registered in PROSPERO. The methodology and proposed analysis is appropriate.
VERSION 1 -AUTHOR RESPONSE
Reviewer: 1 Response: Thank you for the comments. We will include low molecular weight iron dextran and ferumoxytol preparations, along with the trade names for other formulations in our review. An updated search will be performed.
Reviewer: 2 Response: Thank you for the comments. The update is using a more expansive search criteria that the first meta-analysis as we are also collecting data from observational studies. We will incorporate the iron preparations mentioned and the typographical errors have been corrected.
Reviewer: 3 Response: Thank you for these helpful and clinically important suggestions. We will create subgroup analyses for these. Regarding point 3, we recognise the importance of endemic/'background' rate of infection. In order to investigate this, and following discussion with a statistician, we will perform random effects meta-regression to adjust for differences in 'background' / baseline risk of infection. The control group incidence of infection will be used as the background rate and modelled as a continuous variable. The major limitation would be that there may not be sufficient power for the metaregression. Studies do not always provide data on incidence of infection and definitions of infection will vary across studies.
Reviewer: 4 Response: Thank you for the comments. These have all been corrected. Regarding point 1, we wish to clarify that we are only discussing the results of two reviews and not several. This has been rephrased to minimise any reader concerns.
Reviewer: 5 Thank you for the positive comments. 
VERSION 2 -REVIEW REVIEWER
